title: Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Italy massimiliano.bonifacio@univr.it.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bonifacio
authors.affiliation: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors.forename: Gianni
authors.initials: G
authors.lastname: Binotto
authors.affiliation: Hematology Unit, Dell'Angelo Hospital, Venezia-Mestre, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Maino
authors.affiliation: Hematology Unit, Ca' Foncello Hospital, Treviso, Italy.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Calistri
authors.affiliation: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
authors.forename: Luciana
authors.initials: L
authors.lastname: Marin
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Scaffidi
authors.affiliation: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Frison
authors.affiliation: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: De Marchi
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Krampera
authors.affiliation: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Semenzato
authors.affiliation: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors.forename: Achille
authors.initials: A
authors.lastname: Ambrosetti
authors.affiliation: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Tiribelli
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: discordant response; imatinib-treated CML
references.citation: J Natl Compr Canc Netw. 2013 Nov;11(11):1327-40
references.pmid: 24225967
references.citation: Leukemia. 2012 Oct;26(10):2172-5
references.pmid: 22504141
references.citation: Leukemia. 2012 Sep;26(9):2096-102
references.pmid: 22446502
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Blood. 1984 Apr;63(4):789-99
references.pmid: 6584184
references.citation: Blood. 2013 Jun 13;121(24):4867-74
references.pmid: 23620574
references.citation: Blood. 2011 Jul 21;118(3):686-92
references.pmid: 21536864
references.citation: Blood. 2013 Aug 8;122(6):872-84
references.pmid: 23803709
references.citation: J Clin Oncol. 2012 Jan 20;30(3):232-8
references.pmid: 22067393